Form 4: Baxter International EVP Heather Knight Reports Acquisition of Restricted Stock Units

Heather Knight, EVP, Group President, Medical Products at Baxter International, reported the acquisition of restricted stock units (RSUs) as part of her annual equity grant.

Summary

• Heather Knight, an Executive Vice President at Baxter International Inc., filed a Form 4 on March 8, 2024, reporting a transaction that occurred on March 6, 2024.
• The transaction involved the acquisition of 107,168 shares of Baxter's common stock, valued at $0, through an equity grant.
• Following the transaction, Knight directly owns 160,330 shares of Baxter's common stock.
• The equity grant consisted solely of restricted stock units (RSUs) that vest in three equal annual installments starting March 6, 2025, subject to certain vesting requirements under the Baxter International Inc. 2021 Incentive Plan.
• Knight has also granted power of attorney to David S. Rosenbloom, Ellen K. Bradford, and Kimberly Olson to execute and file Forms 4, 5, and 144 on her behalf.

Sentiment

Score: 6

Explanation: The document reflects a neutral sentiment as it primarily reports a routine transaction related to executive compensation. It doesn't contain any overtly positive or negative information.

Positives

• The acquisition of RSUs indicates a long-term commitment to Baxter International by Heather Knight.
• The vesting schedule aligns Knight's interests with the company's performance over the next three years.

Future Outlook

The RSUs are scheduled to vest in three equal annual installments beginning on March 6, 2025, subject to the vesting requirements outlined in the Baxter International Inc. 2021 Incentive Plan.

Industry Context

Form 4 filings are routine disclosures required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. This filing indicates standard executive compensation practices.

Comparison to Industry Standards

• Equity grants, including RSUs, are a common component of executive compensation packages in publicly traded companies like Baxter International.
• Companies such as Medtronic, Johnson & Johnson, and Abbott Laboratories also utilize similar equity-based compensation plans to incentivize and retain key executives.
• The vesting schedules for RSUs typically range from three to five years, aligning with industry norms for long-term incentive programs.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and ownership.

Key Dates